INSPIRE MEDICAL SYSTEMS INC (INSP)

Sector: Health Care

    Home/Companies/INSP/Annual Meeting

2026 Annual Meeting Analysis

INSPIRE MEDICAL SYSTEMS INC · Meeting: April 30, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

0

Directors AGAINST

3

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Gary L. Ellis, Georgia Melenikiotou, and Dana G. Mead, Jr. as Class II Directors

/3 AGAINST

Against Analysis

✗ AGAINST
Gary L. EllisTSR underperformance trigger: INSP 3-year return -78.8% vs peer median -23.6%, gap of -55.2pp exceeds 20pp threshold for negative absolute TSR; 5-year gap -38.1pp also exceeds 20pp threshold — no 5-year mitigant applies; director on board since 2019, well within underperformance period

Mr. Ellis has served since 2019 and his full tenure overlaps the severe underperformance period during which Inspire's stock fell roughly 79% while the company's own peer group fell only about 24%, a gap of 55 percentage points that far exceeds the 20-point trigger threshold for companies with negative absolute returns; the 5-year check does not rescue the vote because the 5-year gap of 38 percentage points also exceeds the same threshold.

✗ AGAINST
Georgia MelenikiotouTSR underperformance trigger: INSP 3-year return -78.8% vs peer median -23.6%, gap of -55.2pp exceeds 20pp threshold for negative absolute TSR; 5-year gap -38.1pp also exceeds 20pp threshold; director on board since 2020, well within underperformance period

Ms. Melenikiotou has served since 2020 and her tenure fully overlaps the period of severe stock underperformance; Inspire's shares fell roughly 79% over three years while the peer group fell only about 24%, a 55-percentage-point gap that triggers a vote against under policy, and the 5-year check (38-point gap) does not provide relief.

✗ AGAINST
Dana G. Mead, Jr.TSR underperformance trigger: INSP 3-year return -78.8% vs peer median -23.6%, gap of -55.2pp exceeds 20pp threshold for negative absolute TSR; 5-year gap -38.1pp also exceeds 20pp threshold; director on board since 2008, well within underperformance period

Mr. Mead has served since 2008 and has been on the board for the entirety of the underperformance period; Inspire's stock declined roughly 79% over three years against a peer group decline of only about 24%, a 55-percentage-point gap well above the 20-point trigger, and the 5-year record (38-point gap) confirms this is sustained rather than transient underperformance.

For Analysis

All three Class II nominees are voted AGAINST under the TSR underperformance trigger. Inspire's stock has lost approximately 79% over three years while its own disclosed compensation peer group declined only about 24%, producing a 55-percentage-point gap that far exceeds the 20-point policy threshold applicable to companies with negative absolute returns. The 5-year check (38-point gap against the same peer group) confirms that this is not a short-term blip within a longer period of adequate performance, so no mitigant applies. All three directors have tenures that meaningfully overlap the underperformance period. No overboarding, attendance, or qualifications concerns were identified.

Say on Pay

✓ FOR

CEO

Timothy P. Herbert

Total Comp

$7,711,784

Prior Support

93%%

The CEO's total reported compensation of approximately $7.7 million is within a reasonable range for the head of a medical-device company with roughly $912 million in revenue and a $1.6 billion market cap; the pay structure is heavily performance-oriented, with roughly 90% of the CEO's target pay at risk through performance stock awards (tied to three-year cumulative revenue and operating income goals) and time-vested restricted stock awards, well above the 50-60% variable-pay threshold required by policy. The prior year say-on-pay vote received 93% support, far above the 70% threshold that would require a remediation response, and the company's clawback policy meets SEC and NYSE requirements.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

11 yrs

Audit Fees

$949,280

Non-Audit Fees

$302,514

Ernst & Young LLP has served since 2015 (approximately 11 years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees (audit-related fees of $43,833 plus tax compliance of $69,585 plus other tax services of $189,096, totaling approximately $302,514) represent about 32% of core audit fees of $949,280, comfortably below the 50% threshold; and EY is a Big 4 firm appropriate for a $1.6 billion market-cap company.

Stockholder Proposals

1 proposal submitted by shareholders

Proposal 5

Approve an Amendment to Our Seventh Amended and Restated Certificate of Incorporation to Phase Out the Classified Board Structure and Provide for the Annual Election of All Directors Beginning with Our 2029 Annual Meeting of Stockholders

✓ FOR
Filed by:Board of Directors (management proposal)OtherCharter Amendment
Board recommends: FOR
Governance improvement: moves from classified (staggered three-year terms) board to annual director elections by 2029Board-initiated in direct response to shareholder feedback on classified structurePhased transition preserves continuity while improving accountability

This is a board-proposed charter amendment that would eliminate the current classified board structure — under which directors serve staggered three-year terms — and replace it with annual elections for all directors starting at the 2029 annual meeting, a mainstream governance improvement that gives shareholders meaningful annual accountability over the full board. The board initiated this change directly in response to shareholder feedback received during 2025 engagement, which is a positive sign of responsiveness. Even though the transition is phased (full annual elections do not begin until 2029), moving from a fully classified board to annual elections is a clear improvement in shareholder rights that policy supports.

Overall Assessment

The most significant votes at Inspire's 2026 annual meeting are the three Class II director elections, where all three nominees — Ellis, Melenikiotou, and Mead — receive AGAINST determinations because Inspire's stock has lost roughly 79% over three years while its own peer group fell only about 24%, a 55-percentage-point gap that far exceeds the policy trigger; the say-on-pay and auditor ratification proposals both pass cleanly, and the board-initiated proposal to phase out the classified board structure and move to annual director elections is supported as a genuine governance improvement driven by shareholder feedback.

Filing date: March 20, 2026·Policy v1.2·high confidence

Compensation Peer Group

20 companies disclosed in 2026 proxy filing

ATRCAtricure, Inc.
CERTCertara, Inc.
CNMDCONMED Corporation
DOCSDoximity, Inc.
GKOSGlaukos Corporation
GMEDGlobus Medical, Inc.
HAEHaemonetics Corporation
NARIInari Medical, Inc.
PODDInsulet Corporation
IARTIntegra LifeSciences Holdings Corporation
IRTCiRhythm Technologies, Inc.
LNTHLantheus Holdings, Inc.
MASIMasimo Corporation
MMSIMerit Medical Systems, Inc.
NTRANatera, Inc.
NEOGNeogen Corporation
NVRONevro Corp.
PENPenumbra, Inc.
STAASTAAR Surgical Company
TNDMTandem Diabetes Care, Inc.